Login to Your Account



Clinic Roundup


Monday, June 4, 2012
• Oncothyreon Inc., of Seattle, said it started a Phase I/II trial of PX-866, its small-molecule PI3K inhibitor, in combination with Zelboraf (vemurafenib, Roche AG).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription